Dr. Niraj H. Mehta, M.D.
Radiation Oncology (Radiation Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 37
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Radiation Oncology Physician primary
FL license ME 116959 · CA license A103983 (first issued 2008; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Glendale Adventist Medical Center Glendale, CA
Medical groups
- Genesiscare USA of Florida LLC (173 clinicians)
- Glendale Adventist Medical Center (103 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 37
- Services billed
- 699
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 276 | 12 |
| Ct guidance for insertion of radiation therapy fields | 170 | 12 |
| Continuing radiation therapy consultation per week | 69 | 19 |
| Calculation of radiation therapy dose | 69 | 16 |
| Radiation treatment management, 5 treatment sessions | 48 | 14 |
| Established patient office or other outpatient visit, 10-19 minutes | 38 | 28 |
| Design and construction of radiation treatment device for high precision radiation therapy | 21 | 13 |
| High precision radiation therapy planning | 18 | 14 |
| Design and construction of complex radiation treatment device | 18 | 15 |
| Complex radiation therapy planning | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 116 |
| Tamsulosin Hcl Other prescribers in Pembroke Pines, FL | 95 |
| Lupron Depot (leuprolide acetate) | 67 |
| Erleada (apalutamide) | 36 |
| Xtandi (enzalutamide) | 28 |
| Eligard (leuprolide acetate) | 20 |
| Sildenafil Citrate Other prescribers in Pembroke Pines, FL | 18 |
| Myrbetriq (mirabegron) Other prescribers in Pembroke Pines, FL | 16 |
| Bicalutamide | 13 |
| Triamcinolone Acetonide Other prescribers in Pembroke Pines, FL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 44 payments worth $1,181 in total to this clinician.
| Janssen Biotech, Inc. | $211 |
|---|---|
| Sumitomo Pharma America, Inc. | $180 |
| Brainlab, Inc. | $167 |
| Pfizer Inc. | $118 |
| Bayer HealthCare Pharmaceuticals Inc. | $108 |
| Teleflex LLC | $87.08 |
| Bioprotect Medical, Inc. | $46.18 |
| Novocure Inc. | $45.72 |
| Food and Beverage | $1,181 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,500 in research payments for these studies, mostly to the institutions running them.
- A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.